Ozempic and Other GLP‑1 Drugs Linked to Rapid Facial Changes and Skin Concerns

Rapid weight loss induced by GLP‑1 receptor agonists such as Ozempic, Wegovy, and Mounjaro is prompting a surge of reports about noticeable facial changes, popularly dubbed “Ozempic face.” Celebrities including Rosie O’Donnell and Jackée Harry have spoken about hollow cheeks, sagging skin and increased wrinkles after losing large amounts of weight quickly. Plastic surgeons and dermatologists explain that the drugs themselves are not the direct cause; instead, swift loss of facial fat outpaces skin’s ability to retract, leading to volume loss and sagging.

Medical experts advise a gradual weight‑loss approach, adequate nutrition, hydration and skin‑care routines to lessen these effects. Non‑surgical options such as fillers and Botox are available, and surgical removal of excess skin may be considered for severe cases. They also warn against unsupervised use of GLP‑1 medications and the rise of counterfeit products, urging stronger regulatory oversight.

Beyond cosmetic concerns, researchers note that GLP‑1 drugs suppress appetite by acting on brain reward pathways, which may also dampen other hedonic drives such as cravings for alcohol, nicotine, gambling or even romantic desire. The broader behavioral implications are under investigation as the drugs become widely used for weight management worldwide.